What guidance, if any, did management provide for Q3 2025 and the full‑year 2025 outlook?

Guidance Update:

In the August 11, 2025 release BioCardia’s management did not issue any specific revenue or cash‑flow guidance for the upcoming third quarter of 2025 nor for the full‑year 2025 period. The filing simply presented the Q2 2025 financial highlights and announced a conference call to discuss the results, but no forward‑looking estimates or targets were disclosed.

Trading Implications:

The absence of a Q3 or FY 2025 outlook leaves the market with heightened uncertainty around the company’s growth trajectory and cash‑burn rate. In such cases, price action often reflects a “wait‑and‑see” bias until the next guidance update—typically after the Q3 earnings call or a subsequent capital‑raise announcement. From a technical standpoint, BioCardia’s shares have been trading in a tight range around the recent Q2 results, with the 20‑day moving average acting as a key support level. Until management provides a concrete outlook, a cautious, range‑bound strategy (e.g., buying on dips near the moving‑average support with a tight stop just below) may be appropriate for short‑term traders. Longer‑term investors should hold off on position sizing until the Q3 guidance is released, as that will be the primary catalyst to define the stock’s upside potential for the remainder of 2025.